Treatment With Infliximab in a Medical Setting (Study P05587)

NCT00752622 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped Factors that led to termination: recruitment challenges and a lower incidence of flares than estimated, causing a high risk of the study being underpowered.

Conditions

Crohn's Disease

Interventions

BIOLOGICAL: Infliximab 5 mg/kg
BIOLOGICAL: Infliximab 5 mg/kg every 6 weeks
BIOLOGICAL: Infliximab 7 mg/kg every 8 weeks

Sponsor

Merck Sharp & Dohme LLC